日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase I Study of (131)I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.

(131)I-间碘苄胍联合Dinutuximab±Vorinostat治疗复发或难治性神经母细胞瘤患者的I期研究:神经母细胞瘤治疗新方法试验

Cash Thomas, Marachelian Araz, DuBois Steven G, Chi Yueh-Yun, Baregamyan Anahit, Groshen Susan G, Jonus Hunter C, Shamirian Anasheh, Crowley Mary, Goodarzian Fariba, Acharya Patricia T, Pawel Bruce, Erbe Amy K, Shahi Ankita, Zaborek Jen, Kennedy Eleanor, Asgharzadeh Shahab, Villablanca Judith G, Pinto Navin, Weiss Brian D, Mosse Yael P, Desai Ami V, Macy Margaret E, Granger Meaghan, Vo Kieuhoa T, Sondel Paul M, Matthay Katherine K, Park Julie R, Goldsmith Kelly C

Central memory-enriched Vγ9Vδ2 γδ T cells via TGF-β expansion demonstrate enhanced in vivo efficacy against metastatic osteosarcoma

通过TGF-β扩增富集中央记忆的Vγ9Vδ2 γδ T细胞,在体内对转移性骨肉瘤表现出增强的疗效。

Silva, Jordan A; Gunasinghe, Kokila; Jonus, Hunter C; Branella, Gianna M; Schiaffino Bustamante, Austre Y; Okalova, Jennifer; Yustein, Jason T; Spencer, H Trent

Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin

使用核输出抑制剂靶向治疗组织学良好的 Wilms 肿瘤中的 TRIP13,可与阿霉素产生协同作用

Karuna Mittal #, Garrett W Cooper #, Benjamin P Lee #, Yongdong Su, Katie T Skinner, Jenny Shim, Hunter C Jonus, Won Jun Kim, Mihir Doshi, Diego Almanza, Bryan D Kynnap, Amanda L Christie, Xiaoping Yang, Glenn S Cowley, Brittaney A Leeper, Christopher L Morton, Bhakti Dwivedi, Taylor Lawrence, Manal

Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma

鉴定并靶向蛋白酪氨酸激酶7 (PTK7) 作为神经母细胞瘤的免疫治疗候选靶点

Jasmine Y Lee ,Hunter C Jonus ,Arhanti Sadanand ,Gianna M Branella ,Victor Maximov ,Suttipong Suttapitugsakul ,Matthew J Schniederjan ,Jenny Shim ,Andrew Ho ,Kiran K Parwani ,Andrew Fedanov ,Adeiye A Pilgrim ,Jordan A Silva ,Robert W Schnepp ,Christopher B Doering ,Ronghu Wu ,H Trent Spencer ,Kelly C Goldsmith

A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors

一项针对复发和/或难治性实体瘤和中枢神经系统肿瘤患儿的辛伐他汀联合拓扑替康和环磷酰胺的1期研究

Cash, Thomas; Jonus, Hunter C; Tsvetkova, Maya; Beumer, Jan H; Sadanand, Arhanti; Lee, Jasmine Y; Henry, Curtis J; Aguilera, Dolly; Harvey, R Donald; Goldsmith, Kelly C

The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of ST8SIA1

是相关蛋白 (YAP) 与神经母细胞瘤对抗 GD2 免疫疗法的耐药性有关,这是通过下调 ST8SIA1 实现的

Adeiye A Pilgrim, Hunter C Jonus, Andrew Ho, Anna C Cole, Jenny Shim, Kelly C Goldsmith

Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials

解析体外γδ T细胞扩增的细胞成分,以优化神经母细胞瘤免疫治疗试验中有效细胞治疗供体的选择

Jonus, Hunter C; Burnham, Rebecca E; Ho, Andrew; Pilgrim, Adeiye A; Shim, Jenny; Doering, Christopher B; Spencer, H Trent; Goldsmith, Kelly C

High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells

高通量筛选证实 Idasanutlin 是针对 Venetoclax 耐药神经母细胞瘤细胞的复敏药物

Lindy Vernooij #, Laurel T Bate-Eya #, Lindy K Alles, Jasmine Y Lee, Bianca Koopmans, Hunter C Jonus, Nil A Schubert, Linda Schild, Daphne Lelieveld, David A Egan, Mark Kerstjens, Ronald W Stam, Jan Koster, Kelly C Goldsmith, Jan J Molenaar, M Emmy M Dolman

YAP-Mediated Repression of HRK Regulates Tumor Growth, Therapy Response, and Survival Under Tumor Environmental Stress in Neuroblastoma

YAP 介导的 HRK 抑制调节神经母细胞瘤在肿瘤环境压力下的肿瘤生长、治疗反应和生存

Jenny Shim, Jasmine Y Lee, Hunter C Jonus, Amanda Arnold, Robert W Schnepp, Kaitlyn M Janssen, Victor Maximov, Kelly C Goldsmith

Thiamine mimetics sulbutiamine and benfotiamine as a nutraceutical approach to anticancer therapy

硫胺素类似物舒布硫胺和苯磷硫胺作为抗癌治疗的营养方法

Hunter C Jonus, Charnel C Byrnes, Jaeah Kim, Maria L Valle, Michael G Bartlett, Hamid M Said, Jason A Zastre